390 related articles for article (PubMed ID: 33276807)
21. Relationships among psychoneurological symptoms and levels of C-reactive protein over 2 years in women with early-stage breast cancer.
Starkweather A; Kelly DL; Thacker L; Wright ML; Jackson-Cook CK; Lyon DE
Support Care Cancer; 2017 Jan; 25(1):167-176. PubMed ID: 27599815
[TBL] [Abstract][Full Text] [Related]
22. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
Martín M; Lluch A; Seguí MA; Ruiz A; Ramos M; Adrover E; Rodríguez-Lescure A; Grosse R; Calvo L; Fernandez-Chacón C; Roset M; Antón A; Isla D; del Prado PM; Iglesias L; Zaluski J; Arcusa A; López-Vega JM; Muñoz M; Mel JR
Ann Oncol; 2006 Aug; 17(8):1205-12. PubMed ID: 16766587
[TBL] [Abstract][Full Text] [Related]
23. Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: a 1-year longitudinal study.
Underwood EA; Jerzak KJ; Lebovic G; Rochon PA; Elser C; Pritchard KI; Tierney MC
Support Care Cancer; 2019 Aug; 27(8):3035-3043. PubMed ID: 30610433
[TBL] [Abstract][Full Text] [Related]
24. Dysregulation of Telomere Lengths and Telomerase Activity in Myelodysplastic Syndrome.
Park HS; Choi J; See CJ; Kim JA; Park SN; Im K; Kim SM; Lee DS; Hwang SM
Ann Lab Med; 2017 May; 37(3):195-203. PubMed ID: 28224765
[TBL] [Abstract][Full Text] [Related]
25. Mindfulness-based cancer recovery and supportive-expressive therapy maintain telomere length relative to controls in distressed breast cancer survivors.
Carlson LE; Beattie TL; Giese-Davis J; Faris P; Tamagawa R; Fick LJ; Degelman ES; Speca M
Cancer; 2015 Feb; 121(3):476-84. PubMed ID: 25367403
[TBL] [Abstract][Full Text] [Related]
26. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study.
Schilder CM; Eggens PC; Seynaeve C; Linn SC; Boogerd W; Gundy CM; Beex LV; Van Dam FS; Schagen SB
Acta Oncol; 2009; 48(1):76-85. PubMed ID: 18777410
[TBL] [Abstract][Full Text] [Related]
27. Telomere deficiencies on chromosomes 9p, 15p, 15q and Xp: potential biomarkers for breast cancer risk.
Zheng YL; Zhou X; Loffredo CA; Shields PG; Sun B
Hum Mol Genet; 2011 Jan; 20(2):378-86. PubMed ID: 20956286
[TBL] [Abstract][Full Text] [Related]
28. Relationship between telomere shortening and age in Korean individuals with mild cognitive impairment and Alzheimer's disease compared to that in healthy controls.
Lee EH; Han MH; Ha J; Park HH; Koh SH; Choi SH; Lee JH
Aging (Albany NY); 2020 Dec; 13(2):2089-2100. PubMed ID: 33323554
[TBL] [Abstract][Full Text] [Related]
29. Cognition, quality-of-life, and symptom clusters in breast cancer: Using Bayesian networks to elucidate complex relationships.
Xu S; Thompson W; Ancoli-Israel S; Liu L; Palmer B; Natarajan L
Psychooncology; 2018 Mar; 27(3):802-809. PubMed ID: 29055062
[TBL] [Abstract][Full Text] [Related]
30. The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
Leinert E; Singer S; Janni W; Harbeck N; Weissenbacher T; Rack B; Augustin D; Wischnik A; Kiechle M; Ettl J; Fink V; Schwentner L; Eichler M
Clin Breast Cancer; 2017 Apr; 17(2):100-106. PubMed ID: 27884722
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
Jones SE; Collea R; Paul D; Sedlacek S; Favret AM; Gore I; Lindquist DL; Holmes FA; Allison MAK; Brooks BD; Portillo RM; Vukelja SJ; Steinberg MS; Stokoe C; Crockett MW; Wang Y; Asmar L; Robert NJ; O'Shaughnessy J
Lancet Oncol; 2013 Oct; 14(11):1121-1128. PubMed ID: 24007746
[TBL] [Abstract][Full Text] [Related]
32. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
Lyman GH; Dale DC; Tomita D; Whittaker S; Crawford J
Breast Cancer Res Treat; 2013 Jun; 139(3):863-72. PubMed ID: 23771731
[TBL] [Abstract][Full Text] [Related]
33. Variability of patterns of fatigue and quality of life over time based on different breast cancer adjuvant chemotherapy regimens.
Berger AM; Lockhart K; Agrawal S
Oncol Nurs Forum; 2009 Sep; 36(5):563-70. PubMed ID: 19726396
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
35. Chromosome 9 arm-specific telomere length and breast cancer risk.
Zheng YL; Loffredo CA; Shields PG; Selim SM
Carcinogenesis; 2009 Aug; 30(8):1380-6. PubMed ID: 19535548
[TBL] [Abstract][Full Text] [Related]
36. Evolutionary hypothesis of telomere length in primary breast cancer and brain tumour patients: a tracer for genomic-tumour heterogeneity and instability.
Mehdipour P; Kheirollahi M; Mehrazin M; Kamalian N; Atri M
Cell Biol Int; 2011 Sep; 35(9):915-25. PubMed ID: 21385157
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal impact of yoga on chemotherapy-related cognitive impairment and quality of life in women with early stage breast cancer: a case series.
Galantino ML; Greene L; Daniels L; Dooley B; Muscatello L; O'Donnell L
Explore (NY); 2012; 8(2):127-35. PubMed ID: 22385567
[TBL] [Abstract][Full Text] [Related]
38. Cognitive impairments in breast cancer survivors treated with chemotherapy: a study based on event-related potentials.
Xu Z; Luo F; Wang Y; Zou BS; Man Y; Liu JS; Li H; Arshad B; Li H; Li S; Wei YX; Li HY; Wu KN; Kong LQ
Cancer Chemother Pharmacol; 2020 Jan; 85(1):61-67. PubMed ID: 31745592
[TBL] [Abstract][Full Text] [Related]
39. Associations of differentially expressed genes with psychoneurological symptoms in patients with head and neck cancer: A longitudinal study.
Lin Y; Peng G; Bruner DW; Miller AH; Saba NF; Higgins KA; Shin DM; Claussen H; Johnston HR; Houser MC; Wommack EC; Xiao C
J Psychosom Res; 2023 Dec; 175():111518. PubMed ID: 37832274
[TBL] [Abstract][Full Text] [Related]
40. Role of taxanes in chemotherapy-related cognitive impairment: A prospective longitudinal study.
Cerulla N; Arcusa À; Navarro JB; Garolera M; Enero C; Chico G; Fernández-Morales L
Breast Cancer Res Treat; 2017 Jul; 164(1):179-187. PubMed ID: 28421379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
